III. Medizinische Klinik (Hämatologie und Onkologie)



Publikationen der III. Medizinischen Klinik

2017

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.
The target landscape of clinical kinase drugs.
Science. 2017 Dec 1;358(6367)

Fischer JC, Otten V, Steiger K, Schmickl M, Slotta-Huspenina J, Beyaert R, van Loo G, Peschel C, Poeck H, Haas T, Spoerl S.
A20 deletion in T cells modulates acute graft-versus-host disease in mice.
Eur J Immunol. 2017 Nov;47(11):1982-1988.

Fischer JC, Otten V, Kober M, Drees C, Rosenbaum M, Schmickl M, Heidegger S, Beyaert R, van Loo G, Li XC, Peschel C, Schmidt-Supprian M, Haas T, Spoerl S, Poeck H.
A20 Restrains Thymic Regulatory T Cell Development.
J Immunol. 2017 Oct 1;199(7):2356-2365.

Knop S, Langer C, Engelhardt M, Mügge LO, Reichle A, Rösler W, Bassermann F, Hertenstein B, Kunitz A, Röllig C, Ostermann H, Schäfer-Eckart K, Ringhoffer M, Günther A, Junghanss C, Biersack H, Schreder M, Liebert A, Held S, Einsele H, Bargou RC.
Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.
Leukemia. 2017 Aug;31(8):1816-1819.

Einsele H, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Engelhardt M, Fischer T, Liebisch P, Straka C.
Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.
Leukemia. 2017 Jun;31(6):1463-1466.

Yusufi N, Mall S, Bianchi HO, Steiger K, Reder S, Klar R, Audehm S, Mustafa M, Nekolla S, Peschel C, Schwaiger M, Krackhardt AM, D'Alessandria C.
In-depth Characterization of a TCR-specific Tracer for Sensitive Detection of Tumor-directed Transgenic T Cells by Immuno-PET.
Theranostics. 2017 Jun 15;7(9):2402-2416.

Kessel KA, Vogel MM, Kessel C, Bier H, Biedermann T, Friess H, Herschbach P, von Eisenhart-Rothe R, Meyer B, Kiechle M, Keller U, Peschel C, Schmid RM, Combs SE.
Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care.
JMIR Mhealth Uhealth. 2017 Jun 14;5(6):e81.

Krönke J, Kuchenbauer F, Kull M, Teleanu V, Bullinger L, Bunjes D, Greiner A, Kolmus S, Köpff S, Schreder M, Mügge LO, Straka C, Engelhardt M, Döhner H, Einsele H, Bassermann F, Bargou R, Knop S, Langer C.
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Leukemia. 2017 Jun;31(6):1363-1367.

Haas T, Heidegger S, Wintges A, Bscheider M, Bek S, Fischer JC, Eisenkolb G, Schmickl M, Spoerl S, Peschel C, Poeck H, Ruland J.
Card9 controls Dectin-1-induced T-cell cytotoxicity and tumor growth in mice.
Eur J Immunol. 2017 May;47(5):872-879.

Fischer JC, Bscheider M, Eisenkolb G, Lin CC, Wintges A, Otten V, Lindemans CA, Heidegger S, Rudelius M, Monette S, Porosnicu Rodriguez KA, Calafiore M, Liebermann S, Liu C, Lienenklaus S, Weiss S, Kalinke U, Ruland J, Peschel C, Shono Y, Docampo M, Velardi E, Jenq RR, Hanash AM, Dudakov JA, Haas T, van den Brink MRM, Poeck H.
RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury.
Sci Transl Med. 2017 Apr 19;9(386).

Drees C, Vahl JC, Bortoluzzi S, Heger KD, Fischer JC, Wunderlich FT, Peschel C, Schmidt-Supprian M.
Roquin Paralogs Differentially Regulate Functional NKT Cell Subsets.
J Immunol. 2017 Apr 1;198(7):2747-2759.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
N Engl J Med. 2017 Mar 9;376(10):917-927.

Schreck C, Istvánffy R, Ziegenhain C, Sippenauer T, Ruf F, Henkel L, Gärtner F, Vieth B, Florian MC, Mende N, Taubenberger A, Prendergast Á, Wagner A, Pagel C, Grziwok S, Götze KS, Guck J, Dean DC, Massberg S, Essers M, Waskow C, Geiger H, Schiemann M, Peschel C, Enard W, Oostendorp RA.
Niche WNT5A regulates the actin cytoskeleton during regeneration of hematopoietic stem cells.
J Exp Med. 2017 Jan;214(1):165-181. doi: 10.1084/jem.20151414.

2016

Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, Martignoni ME, Werner A, Hein R, H Busch D, Peschel C, Rad R, Cox J, Mann M, Krackhardt AM.
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.
Nat Commun. 2016 Nov 21;7:13404. doi: 10.1038/ncomms13404.

Spoerl S, Peter R, Wäscher D, Götze K, Verbeek M, Peschel C, Krackhardt AM.
Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
Transfusion. 2016 Nov 18. doi: 10.1111/trf.13883. [Epub ahead of print]

Kessel KA, Lettner S, Kessel C, Bier H, Biedermann T, Friess H, Herrschbach P, Gschwend JE, Meyer B, Peschel C, Schmid R, Schwaiger M, Wolff KD, Combs SE.
Use of Complementary and Alternative Medicine (CAM) as Part of the Oncological Treatment: Survey about Patients' Attitude towards CAM in a University-Based Oncology Center in Germany.
PLoS One. 2016 Nov 3;11(11):e0165801. doi: 10.1371/journal.pone.0165801.

Groß CJ, Mishra R, Schneider KS, Médard G, Wettmarshausen J, Dittlein DC, Shi H, Gorka O, Koenig PA, Fromm S, Magnani G, Ćiković T, Hartjes L, Smollich J, Robertson AA, Cooper MA, Schmidt-Supprian M, Schuster M, Schroder K, Broz P, Traidl-Hoffmann C, Beutler B, Kuster B, Ruland J, Schneider S, Perocchi F, Groß O.
K+ Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria.
Immunity. 2016 Oct 18;45(4):761-773

Mall S, Yusufi N, Wagner R, Klar R, Bianchi H, Steiger K, Straub M, Audehm S, Laitinen I, Aichler M, Peschel C, Ziegler S, Mustafa M, Schwaiger M, D'Alessandria C, Krackhardt AM.
Immuno-PET Imaging of Engineered Human T Cells in Tumors.
Cancer Res. 2016 Jun 28. 


Derudder E, Herzog S, Labi V, Yasuda T, Köchert K, Janz M, Villunger A, Schmidt-Supprian M, Rajewsky K.
Canonical NF-κB signaling is uniquely required for the long-term persistence of functional mature B cells.
Proc Natl Acad Sci U S A. 2016 May 3;113(18):5065-70

Meininger I, Griesbach RA, Hu D, Gehring T, Seeholzer T, Bertossi A, Kranich J, Oeckinghaus A, Eitelhuber AC, Greczmiel U, Gewies A, Schmidt-Supprian M, Ruland J, Brocker T, Heissmeyer V, Heyd F, Krappmann D.
Alternative splicing of MALT1 controls signalling and activation of CD4(+) T cells.
Nat Commun. 2016 Apr 12;7:11292.

Höckendorf U, Yabal M, Herold T, Munkhbaatar E, Rott S, Jilg S, Kauschinger J, Magnani G, Reisinger F, Heuser M, Kreipe H, Sotlar K, Engleitner T, Rad R, Weichert W, Peschel C, Ruland J, Heikenwalder H, Spiekermann K, Slotta-Huspenina J, Groß O, and Jost PJ.
RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells.
Cancer Cell, 2016, 30, 75-91.

Spinner S, Crispatzu G, Yi JH, Munkhbaatar E, Mayer P, Höckendorf U, Müller N, Li Z, Schader T, Bendz H, Hartmann S, Yabal M, Pechloff K, Heikenwalder M, Kelly GL, Strasser A, Peschel C, Hansmann ML, Ruland J, Keller U, Newrzela S, Herling M, Jost PJ.
Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.
Leukemia. 2016, 30, 1520-30.

Jilg S, Reidel V, Müller-Thomas C, König J, Schauwecker J, Höckendorf U, Huberle C, Gorka O, Schmidt B, Burgkart R, Ruland J, Kolb HJ, Peschel C, Oostendorp RA, Götze KS, Jost PJ.
Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.
Leukemia. 2016, 30, 112-123.

Eichner, R., Heider, M., Fernández-Sáiz, V., van Bebber, F., Garz, A.K., Lemeer, S., Rudelius, M., Targosz, B.S., Jacobs, L., Knorn, A.M., Slawska, J., Platzbecker, U., Germing, U, Langer, C., Knop, S., Einsele, H., Peschel, C., Haass, C., Keller, U., Schmid, B., Götze, K.S., Kuster, B., and Bassermann, F.
Immunomodulatory drugs disrupt the CRBN-CD147/MCT1 axis to exert anti-tumor activity and teratogenicity.

Nature Medicine (2016) in press

Engel, K., Rudelius, M., Slawska, J., Ahangarian Abhari, B., Altmann, B., Kurutz, J., Brunner, A., Targosz, B.S., Loewecke, F., Knorn, A.M., Gloeckner, C.J., Ueffing, M., Fernandez-Sáiz, V., Baumann, U., Fulda, S., Pfreundschuh, M., Trümper, L., Klapper, W., Keller, U., Jost, P.J., Rosenwald, A., Peschel, C., Bassermann, F.
USP9X stabilizes XIAP to regulate mitotic cell death and mediate resistance to anti-tubulin chemotherapeutics in aggressive B-cell lymphoma.

EMBO Mol Med. 2016 Aug 1;8(8):851-62.

Spinner S, Crispatzu G, Yi JH, Munkhbaatar E, Mayer P, Höckendorf U, Müller N, Li Z, Schader T, Bendz H, Hartmann S, Yabal M, Pechloff K, Heikenwalder M, Kelly GL, Strasser A, Peschel C, Hansmann ML, Ruland J, Keller U, Newrzela S, Herling M, Jost PJ.
Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.
Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.49.

Spoerl S, Hendlmeier C, Hapfelmeier A, Wildgruber M, Schmid RM, Peschel C, Saugel B.
Characteristics and outcome of patients presenting to the emergency department after autologous/allogeneic stem cell transplantation.
Eur J Emerg Med. 2016 Mar 21.

Lorenzen S, Arnold D, Fottner C, Leichsenring J, Moehler M, Seufferlein T, Vogel A, Weber MM, Reinacher-Schick A.
ASCO-update 2015 - highlights of the 51. meeting of the american society of clinical oncology/ASCO 2015
Z Gastroenterol. 2016 Feb;54(2):167-72.

Wagner M, Oelsner M, Moore A, Götte F, Kuhn PH, Haferlach T, Fiegl M, Bogner C, Baxter EJ, Peschel C, Follows GA, Ringshausen I.
Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia.
Blood. 2016 Jan 28;127(4):436-48.

2015

Hofheinz RD, Kripp M, Lorenzen S.
Combination of cetuximab with radio-chemotherapy in patients with esophageal cancer: less is more!
J Thorac Dis. 2015 Dec;7(12):E629-32

Istvánffy R, Vilne B, Schreck C, Ruf F, Pagel C, Grziwok S, Henkel L, Prazeres da Costa O, Berndt J, Stümpflen V, Götze KS, Schiemann M, Peschel C, Mewes HW, Oostendorp RA.
Stroma-Derived Connective Tissue Growth Factor Maintains Cell Cycle Progression and Repopulation Activity of Hematopoietic Stem Cells In Vitro.
Stem Cell Reports. 2015 Nov 10;5(5):702-15.

Ridder DA, Wenzel J, Müller K, Töllner K, Tong XK, Assmann JC, Stroobants S, Weber T, Niturad C, Fischer L, Lembrich B, Wolburg H, Grand'Maison M, Papadopoulos P, Korpos E, Truchetet F, Rades D, Sorokin LM, Schmidt-Supprian M, Bedell BJ, Pasparakis M, Balschun D, D'Hooge R, Löscher W, Hamel E, Schwaninger M.
Brain endothelial TAK1 and NEMO safeguard the neurovascular unit.
J Exp Med. 2015 Sep 21;212(10):1529-49. doi: 10.1084/jem.20150165. Epub 2015 Sep 7.

Lorenzen S, Spoerl S,  Al-Batran SE, Feith M, Lordick F, Thuss-Patience P, Haller B, Angele M, Novotny A.
Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer.
Eur J Cancer. 2015 Sep;51(14):1918-26.

Franke K, Vilne B, Da Costa O, Rudelius M, Peschel C, Oostendorp RA, Keller U.
In vivo hematopoietic Myc activation directs a transcriptional signature in endothelial cells within the bone marrow microenvironment.
Oncotarget. 2015 Aug 19.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N.
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
Leukemia. 2015 Jul 31. doi: 10.1038/leu.2015.212.

Metz S, Ganter C, Lorenzen S, van Marwick S, Holzapfel K, Herrmann K, Rummeny EJ, Wester HJ, Schwaiger M, Nekolla SG, Beer AJ.
Multiparametric MR and PET Imaging of Intratumoral Biological Heterogeneity in Patients with Metastatic Lung Cancer Using Voxel-by-Voxel Analysis.
PLoS One. 2015 Jul 17;10(7):e0132386

Drees C, Vahl JC, Schmidt-Supprian M.
TCR signals fuel Treg cells.
Oncotarget. 2015 Jul 12.

Deeb SJ, Tyanova S, Hummel M, Schmidt-Supprian M, Cox J, Mann M.
Machine Learning Based Classification of Diffuse Large B-cell Lymphoma Patients by their Protein Expression Profiles.
Mol Cell Proteomics. 2015 Aug 26. pii: mcp.M115.050245.

Murakawa Y, Hinz M, Mothes J, Schuetz A, Uhl M, Wyler E, Yasuda T, Mastrobuoni G, Friedel CC, Dölken L, Kempa S, Schmidt-Supprian M, Blüthgen N, Backofen R, Heinemann U, Wolf J, Scheidereit C, Landthaler M.
RC3H1 post-transcriptionally regulates A20 mRNA and modulates the activity of the IKK/NF-kB pathway.
Nat Commun. 2015 Jul 14;6:7367.

Spoerl S, Peter R, Wäscher D, Verbeek M, Menzel H, Peschel C, Krackhardt AM.
Long-term experiences in cryopreservation of mobilized peripheral blood stem cells using a closed-bag system: a technology with potential for broader application.
Transfusion. 2015 Jul 14. doi: 10.1111/trf.13206.

Jilg S, Reidel V, Müller-Thomas C, König J, Schauwecker J, Höckendorf U, Huberle C, Gorka O, Schmidt B, Burgkart R, Ruland J, Kolb HJ, Peschel C, Oostendorp RA, Götze KS, Jost PJ.
Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.
Leukemia. 2015 Jul 8. doi: 10.1038/leu.2015.179.

Hoellein A, Hecker J, Hoffmann D, Göttle F, Protzer U, Peschel C, Götze K.
Serious Outbreak of Human Metapneumovirus in Patients with Hematologic Malignancies.
Leuk Lymphoma. 2015 Jun 30:1-15.

Hofheinz RD, Lorenzen S.
Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.
Expert Rev Anticancer Ther. 2015 Jun;15(6):607-14.

Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, Hauck SM, Schuh E, Krumbholz M, Rübsamen H, Wanngren J, Khademi M, Olsson T, Alexander T, Hiepe F, Pfister HW, Weber F, Jenne D, Wekerle H, Hohlfeld R, Lichtenthaler SF, Meinl E.
γ-Secretase directly sheds the survival receptor BCMA from plasma cells.
Nat Commun. 2015 Jun 11;6:7333.

Zhang B, Calado DP, Wang Z, Fröhler S, Köchert K, Qian Y, Koralov SB, Schmidt-Supprian M, Sasaki Y, Unitt C, Rodig S, Chen W, Dalla-Favera R, Alt FW, Pasqualucci L, Rajewsky K.
An Oncogenic Role for Alternative NF-κB Signaling in DLBCL Revealed upon Deregulated BCL6 Expression.
Cell Rep. 2015 May 5;11(5):715-26.

Heger K, Kober M, Rieß D, Drees C, de Vries I, Bertossi A, Roers A, Sixt M, Schmidt-Supprian M.
A novel Cre recombinase reporter mouse strain facilitates selective and efficient infection of primary immune cells with adenoviral vectors.
Eur J Immunol. 2015 Mar 17.

Schreiber S, Hoellein A, Decker T, Jilg S, Dreyling M, Peschel C, Keller U.
Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study.
Leuk Lymphoma. 2015 Mar 31:1-3.

Lorenzen S, Riera Knorrenschild J, Haag GM, Pohl M, Thuss-Patience P, Bassermann F, Helbig U, Weißinger F, Schnoy E, Becker K, Stocker G, Rüschoff J, Eisenmenger A, Karapanagiotou-Schenkel I, Lordick F.
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Eur J Cancer. 2015 Mar;51(5):569-76

Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U.
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.
EMBO Mol Med. 2015 Mar 3. pii: e201404698, doi: 10.15252/emmm.201404698

2014

Vahl JC, Drees C, Heger K, Heink S, Fischer JC, Nedjic J, Ohkura N, Morikawa H, Poeck H, Schallenberg S, Rieß D, Hein MY, Buch T, Polic B, Schönle A, Zeiser R, Schmitt-Gräff A, Kretschmer K, Klein L, Korn T, Sakaguchi S, Schmidt-Supprian M.
Continuous T Cell Receptor Signals Maintain a Functional Regulatory T Cell Pool.
Immunity. 2014 Nov 6;41(5):722-736.

Illert AL, Seitz AK, Rummelt C, Kreutmair S, Engh RA, Goodstal S, Peschel C, Duyster J, von Bubnoff N.
Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells.
PLoS One. 2014 Nov 26;9(11):e112318. doi: 10.1371/journal.pone.0112318. eCollection 2014.

Baumann U, Fernández-Sáiz V, Rudelius M, Lemeer S, Rad R, Knorn AM, Slawska J, Engel K, Jeremias I, Li Z, Tomiatti V, Illert AL, Targosz BS, Braun M, Perner S, Leitges M, Klapper W, Dreyling M, Miething C, Lenz G, Rosenwald A, Peschel C, Keller U, Kuster B, Bassermann F.
Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis.
Nat Med. 2014 Nov 24. doi: 10.1038/nm.3740.

Tomiatti V, Istvánffy R, Pietschmann E, Kratzat S, Hoellein A, Quintanilla-Fend L, von Bubnoff N, Peschel C, Oostendorp RA, Keller U.
Cks1 is a critical regulator of hematopoietic stem cell quiescence and cycling, operating upstream of Cdk inhibitors.
Oncogene. 2014 Nov 24;0. doi: 10.1038/onc.2014.364.

Tsaousidou E, Paeger L, Belgardt BF, Pal M, Wunderlich CM, Brönneke H, Collienne U, Hampel B, Wunderlich FT, Schmidt-Supprian M, Kloppenburg P, Brüning JC.
Distinct Roles for JNK and IKK Activation in Agouti-Related Peptide Neurons in the Development of Obesity and Insulin Resistance.
Cell Reports 2014 Nov 20;9(4):1495-506. doi: 10.1016/j.celrep.2014.10.045

Dechow T, Steidle S, Götze KS, Rudelius M, Behnke K, Pechloff K, Kratzat S, Bullinger L, Fend F, Soberon V, Mitova N, Li Z, Thaler M, Bauer J, Pietschmann E, Albers C, Grundler R, Schmidt-Supprian M, Ruland J, Peschel C, Duyster J, Rose-John S, Bassermann F, Keller U.
GP130 activation induces myeloma and collaborates with MYC.
J Clin Invest. 2014 Nov 10. pii: 69094. doi: 10.1172/JCI69094.

Förster A, Blissenbach B, Machova A, Leja S, Rabenhorst A, Wilmschen S, Heger K, Schmidt-Supprian M, Roers A, Hartmann K, Papadopoulou N.
Dicer is indispensable for the development of murine mast cells.
J Allergy Clin Immunol. 2014 Oct 30. pii: S0091-6749(14)01474-2. doi: 10.1016/j.jaci.2014.10.005.

Huber K, Aichler M, Sun N, Buck A, Li Z, Fernandez IE, Hauck SM, Zitzelsberger H, Eickelberg O, Janssen KP, Keller U, Walch A.
A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies.
Histochem Cell Biol. 2014 Oct;142(4):361-71.

Illert AL, Albers C, Kreutmair S, Leischner H, Peschel C, Miething C, Duyster J.
Grb10 is Involved in BCR-ABL Positive Leukemia in Mice.
Leukemia. 2014 Sep 24. doi: 10.1038/leu.2014.283.

Eigentler TK, Schlaak M, Hassel JC, Loquai C, Stoffels I, Gutzmer R, Pätzold S, Mohr P, Keller U, Starz H, Ulrich J, Tsianakas A, Kähler K, Hauschild A, Janssen E, Schuler-Thurner B, Weide B, Garbe C.
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions.
J Immunother. 2014 Sep;37(7):374-81.

Harrasser N, Banke IJ, Hauschild M, Lenze U, Prodinger PM, Toepfer A, Peschel C, von Eisenhart-Rothe R, Ringshausen I, Verbeek M.
Clinical challenge: fatal mucormycotic osteomyelitis caused by Rhizopus microsporus despite aggressive multimodal treatment.
BMC Infect Dis. 2014 Sep 6;14(1):488. doi: 10.1186/1471-2334-14-488.

Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A, Peschel C, Nilsson JA, Cleveland JL, Keller U.
Myc-induced SUMOylation is a therapeutic vulnerability for B cell lymphoma.
Blood. 2014 Aug 20. pii: blood-2014-06-584524.

Peschke K, Weitzmann A, Heger K, Behrendt R, Schubert N, Scholten J, Voehringer D, Hartmann K, Dudeck A, Schmidt-Supprian M*, Roers A*:
IκB Kinase 2 Is Essential for IgE-Induced Mast Cell De Novo Cytokine Production but Not for Degranulation.
Cell Reports 2014, 8:1300–1307.   
*Corresponding authors

Löhr JM, Haas SL, Kröger JC, Friess HM, Höft R, Goretzki PE, Peschel C, Schweigert M, Salmons B, Gunzburg WH.
Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer.
Pharmaceutics. 2014 Aug 11;6(3):447-66. doi: 10.3390/pharmaceutics6030447. Review.

Istvanffy R, Vilne B, Bock F, Schreck C, Grziwok S, Prazeres da Costa O, Peschel C, Mewes HW, Oostendorp R.
Rapid upregulation of CTGF under stress conditions is required for HSC maintenance through cross-talk of canonical Wnt and AKT signaling.
Exp Hematol. 2014 Aug;42(8 Suppl):S40. doi: 10.1016/j.exphem.2014.07.146. No abstract available.

Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, Hansen HC, Keller UB, McLure KG, Nilsson JA.
BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2721-30.

Heidegger S, Beer AJ, Geissinger E, Rosenwald A, Peschel C, Ringshausen I, Keller U.
Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.
Onco Targets Ther. 2014 Jun 20;7:1123-7. doi: 10.2147/OTT.S59795. eCollection 2014.

Herrmann K, Buck AK, Schuster T, Abbrederis K, Blümel C, Santi I, Rudelius M, Wester HJ, Peschel C, Schwaiger M, Dechow T, Keller U.
Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL.
Oncotarget. 2014 Jun 30;5(12):4050-9.

Müller-Thomas C, Rudelius M, Rondak IC, Haferlach T, Schanz J, Huberle C, Schmidt B, Blaser R, Kremer M, Peschel C, Germing U, Platzbecker U, Götze K.
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Haematologica. 2014 Jun 27. pii: haematol.2014.104760.

Graf N, Li Z, Herrmann K, Weh D, Aichler M, Slawska J, Walch A, Peschel C, Schwaiger M, Buck AK, Dechow T, Keller U.
Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma.
Onco Targets Ther. 2014 May 23;7:789-98.

Yabal M, Müller N, Adler H, Knies N, Groß CJ, Damgaard RB, Kanegane H, Ringelhan M, Kaufmann T, Heikenwälder M, Strasser A, Groß O, Ruland J, Peschel C, Gyrd-Hansen M, Jost PJ.
XIAP Restricts TNF- and RIP3-Dependent Cell Death and Inflammasome Activation.
Cell Rep. 2014 May 28. pii: S2211-1247(14)00383-0.

Klar R, Schober S, Rami M, Mall S, Merl J, Hauck SM, Ueffing M, Admon A, Slotta-Huspenina J, Schwaiger M, Stevanović S, Oostendorp RA, Busch DH, Peschel C, Krackhardt AM.
Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.
Leukemia. 2014 Apr 16. doi: 10.1038/leu.2014.131.

Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, Verbeek M, Fischer J, Otten V, Schmickl M, Maas-Bauer K, Finke J, Peschel C, Duyster J, Poeck H, Zeiser R, von Bubnoff N.
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
Blood. 2014 Jun 12;123(24):3832-42.

Baumgart A, Mazur PK, Anton M, Rudelius M, Schwamborn K, Feuchtinger A, Behnke K, Walch A, Braren R, Peschel C, Duyster J, Siveke JT, Dechow T.
Opposing role of Notch1 and Notch2 in a KrasG12D-driven murine non-small cell lung cancer model.
Oncogene. 2014 Feb 10. doi: 10.1038/onc.2013.592.

Engel K, Rudelius M, Meinel FG, Peschel C, Keller U.
An adult patient with Nijmegen Breakage Syndrome and Hodgkin's Lymphoma.
BMC Hematol. 2014 Jan 16;14(1):2.

2013

Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, Hannesschläger N, Schlee M, Rothenfusser S, Barchet W, Kato H, Akira S, Inoue S, Endres S, Peschel C, Hartmann G, Hornung V, Ruland J.
Addendum: Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1β production.
Nat Immunol. 2013 Dec 18;15(1):109.

Gewies A, Castineiras-Vilarino M, Ferch U, Jährling N, Heinrich K, Hoeckendorf U, Przemeck GK, Munding M, Groß O, Schroeder T, Horsch M, Karran EL, Majid A, Antonowicz S, Beckers J, Hrabé de Angelis M, Dodt HU, Peschel C, Förster I, Dyer MJ, Ruland J.
Prdm6 is essential for cardiovascular development in vivo.
PLoS One. 2013 Nov 21;8(11):e81833. doi: 10.1371/journal.pone.0081833.

Krönig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R, Blank CU.
Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human AML blast cells during treatment.
Eur J Haematol. 2013 Oct 31. doi: 10.1111/ejh.12228.

Florian MC, Nattamai KJ, Dörr K, Marka G, Uberle B, Vas V, Eckl C, Andrä I, Schiemann M, Oostendorp RA, Scharffetter-Kochanek K, Kestler HA, Zheng Y, Geiger H.
A canonical to non-canonical Wnt signalling switch in haematopoietic stem-cell ageing.
Nature. 2013 Oct 20. doi: 10.1038/nature12631.

Jankovic D, Ganesan J, Bscheider M, Stickel N, Weber FC, Guarda G, Follo M, Pfeifer D, Tardivel A, Ludigs K, Bouazzaoui A, Kerl K, Fischer JC, Haas T, Schmitt-Gräff A, Manoharan A, Müller L, Finke J, Martin SF, Gorka O, Peschel C, Ruland J, Idzko M, Duyster J, Holler E, French LE, Poeck H, Contassot E, Zeiser R.
The Nlrp3 inflammasome regulates acute graft-versus-host disease.
J Exp Med. 2013 Aug 26.

Maier J, Lange T, Kerle I, Specht K, Bruegel M, Wickenhauser C, Jost P, Niederwieser D, Peschel C, Duyster J, von Bubnoff N.
Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA.
Clin Cancer Res. 2013 Aug 9.

Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F, Haller B, Schuster T, Pauligk C, Luley K, Bichev D, Schumacher G, Homann N.
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Ann Oncol. 2013 Aug;24(8):2068-73.

Buhmann R, Michael S, Juergen H, Horst L, Peschel C, Kolb HJ.
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.
J Transl Med. 2013 Jul 2;11(1):160.

Eichner R, Essler M, Specht K, Wörtler K, Peschel C, Bassermann F, Ringshausen I.
PET-MRI hybrid imaging in a rare case of B cell lymphoblastic lymphoma with musculoskeletal manifestation.
Ann Hematol. 2013 Jun 18.

Wagner JY, Schwarz K, Schreiber S, Schmidt B, Wester HJ, Schwaiger M, Peschel C, von Schilling C, Scheidhauer K, Keller U.
Myeloablative Anti-CD20 Radioimmunotherapy +/- High-Dose Chemotherapy Followed by Autologous Stem Cell Support for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival.
Oncotarget. 2013 Jun 12.

Menzel H, Hinmüller K, Kolb HJ, Schuster T, Hoellein A, Peschel C, Dechow T, Keller U.
Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma.
Ther Adv Hematol. 2012 Apr;3(2):81-8. doi: 10.1177/2040620711433317.

Bauer RC, Sanger J, Peschel C, Duyster J, von Bubnoff N.
Sequential inhibitor therapy in CML: In vitro simulation elucidates the pattern of resistance mutations after second and third line treatment.
Clin Cancer Res. 2013 Apr 2.

Sigl M, Spoerl S, Schnittger S, Meissner J, Rummelt C, Peschel C, Duyster J, Ho AD, von Bubnoff N.
Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation.
Blood Cancer J. 2013 Mar 8;3:e104. doi: 10.1038/bcj.2013.3. 

Lorenzen S, Pauligk C, Homann N, Schmalenberg H, Jäger E, Al-Batran SE.
Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
Br J Cancer. 2013 Feb 19;108(3):519-26.

Albers C, Leischner H, Verbeek M, Yu C, Illert AL, Peschel C, von Bubnoff N, Duyster J.
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD(+) AML but retains in vitro sensitivity to PKC412 and Sunitinib.
Leukemia. 2013 Jan 16. doi: 10.1038/leu.2013.14.

Ihbe-Heffinger A, Paessens B, Berger K, Shlaen M, Bernard R, von Schilling C, Peschel C.
The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care - an observational analysis on non-small-cell lung cancer patients.
Support Care Cancer. 2013 Jan 23.

Lutzny G, Kocher T, Schmidt-Supprian M, Rudelius M, Klein-Hitpass L, Finch AJ, Dürig J, Wagner M, Haferlach C, Kohlmann A, Schnittger S, Seifert M, Wanninger S, Zaborsky N, Oostendorp R, Ruland J, Leitges M, Kuhnt T, Schäfer Y, Lampl B, Peschel C, Egle A, Ringshausen I.
Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.
Cancer Cell. 2013 Jan 14;23(1):77-92. doi: 10.1016/j.ccr.2012.12.003.

Fernández-Sáiz, V, Targosz, B.S, Lemeer, S, Eichner, R, Langer, C, Bullinger, L, Reiter, C, SlottaHuspenina, J, Schroeder, S, Knorn, A.M., Kurutz, J, Peschel, C, Pagano, M, Kuster, B, and Bassermann, F.
SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma.
Nat Cell Biol. 2013 Jan;15(1):72-81.

Han Y, Yu G, Sarioglu H, Caballero-Martinez A, Schlott F, Ueffing M, Haase H, Peschel C, Krackhardt AM.
Proteomic investigation of the interactome of FMNL1 in hematopoietic cells unveils a role in calcium-dependent membrane plasticity.
J Proteomics. 2013 Jan 14;78:72-82. doi: 10.1016/j.jprot.2012.11.015. Epub 2012 Nov 24. 

Graf N, Herrmann K, Numberger B, Zwisler D, Aichler M, Feuchtinger A, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, Peschel C, Schwaiger M, Keller U, Dechow T, Buck AK.
[(18)F]FLT is superior to [(18)F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.
Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):34-43. doi: 10.1007/s00259-012-2255-0. Epub 2012 Oct 5.

2012

Höfig I, Atkinson MJ, Mall S, Krackhardt AM, Thirio C and Anastasov N
Poloxamer synperonic F108 improves cellular transduction with lentiviral vectors.
J Gene Med. 2012 Aug;14(8):549-60

Weigand LU, Liang X, Schmied S, Mall S, Klar R, Stötzer OJ, Salat C, Götze K, Mautner J, Peschel C, Krackhardt AM.
Isolation of human MHC class II-restricted T cell receptors from the autologous T-cell repertoire with potent anti-leukaemic reactivity.
Immunology. 2012 Nov;137(3):226-38.

Illert AL, Zech M, Moll C, Albers C, Kreutmair S, Peschel C, Bassermann F, Duyster J.
Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of Nuclear interaction partner of Anaplastic lymphoma kinase (NIPA) at G2/M.
J Biol Chem. 2012 Sep 6.

Schweneker K, Gorka O, Schweneker M, Poeck H, Tschopp J, Peschel C, Ruland J, Groß O.
The mycobacterial cord factor adjuvant analogue trehalose-6,6'-dibehenate (TDB) activates the Nlrp3 inflammasome.
Immunobiology. 2012 Aug 7

Eichner R, Wörtler K, Essler M, Rudelius M, Peschel C, Ringshausen I, Götze K.
Symmetric multifocal bone marrow involvement diagnosed by whole-body magnetic resonance imaging in a patient with B lymphoblastic lymphoma.
Ann Hematol. 2012 Aug 19.

Li Z, Graf NA, Herrmann K, Jünger A, Aichler M, Feuchtinger A, Baumgart A, Walch A, Peschel C, Schwaiger M, Buck A, Keller U, Dechow T.
FLT-PET Is Superior to FDG-PET for Very Early Response Prediction in NPM-ALK-Positive Lymphoma Treated with Targeted Therapy.
Cancer Res. 2012 Aug 8.

Decker T, Fischer G, Bücke W, Bücke P, Stotz F, Grüneberger A, Gropp-Meier M, Wiedemann G, Pfeiffer C, Peschel C, Götze K.
Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer.
J Cancer Res Clin Oncol. 2012 Jul 4.

Illert AL, Kawaguchi H, Antinozzi C, Bassermann F, Quintanilla-Martinez L, von Klitzing C, Hiwatari M, Peschel C, de Rooij DG, Morris SW, Barchi M, Duyster J.
Targeted inactivation of nuclear interaction partner of ALK disrupts meiotic prophase.
Development. 2012 Jul;139(14):2523-34.

Kratzat S, Nikolova V, Miething C, Hoellein A, Schoeffmann S, Gorka O, Pietschmann E, Illert AL, Ruland J, Peschel C, Nilsson J, Duyster J, Keller U.
Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignancies.
PLoS One. 2012;7(5):e37433.

Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M, Rieser E, Rickard JA, Bankovacki A, Peschel C, Ruland J, Bekker-Jensen S, Mailand N, Kaufmann T, Strasser A, Walczak H, Silke J, Jost PJ, Gyrd-Hansen M.
The Ubiquitin Ligase XIAP Recruits LUBAC for NOD2 Signaling in Inflammation and Innate Immunity.
Mol Cell. 2012 May 16.

Hoellein A, Graf S, Bassermann F, Schoeffmann S, Platz U, Hölzlwimmer G, Kröger M, Peschel C, Oostendorp R, Quintanilla-Fend L, Keller U.
Cks1 promotes S phase entry and proliferation independent of p27Kip1 suppression.
Mol Cell Biol. 2012 Apr 16.

Leischner H, Albers C, Grundler R, Razumovskaya E, Spiekermann K, Bohlander S, Rönnstrand L, Götze K, Peschel C, Duyster J.
SRC is a signaling mediator in FLT3-ITD but not in FLT3-TKD positive AML.
Blood. 2012 Mar 12.

2011

Klitzing C, Huss R, Illert AL, Fröschl A, Wötzel S, Peschel C, Bassermann F, Duyster J.
APC/C-mediated degradation of the F-box protein NIPA is regulated by its association with Skp1.
PLoS One. 2011;6(12):e28998. Epub 2011 Dec 20.

Biberacher V, Decker T, Oelsner M, Wagner M, Bogner C, Schmidt B, Kreitman RJ, Peschel C, Pastan I, Meyer Zum Buschenfelde C, Ringshausen I.
The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin1 in B-cell lymphomas through CD22 up-regulation and PKC-βII depletion.
Haematologica. 2011 Dec 16

Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Höfler H, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, Lordick F.
Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
BMC Cancer. 2011 Dec 7;11:509.

Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N, Scheuerer C, Peschel C, Schwaiger M, Dechow T, Keller U.
A Pilot Study to Evaluate 3'-Deoxy-3'-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma.
J Nucl Med. 2011 Nov 7.

Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, Duyster J.
Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib.
PLoS One. 2011;6(10):e26760.

Hoellein A, Pickhard A, von Keitz F, Schoeffmann S, Piontek G, Rudelius M, Baumgart A, Wagenpfeil S, Peschel C, Dechow T, Bier H, Keller U.
Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck.
Oncotarget. 2011 Aug;2(8):599-609.

Istvanffy R, Kröger M, Eckl C, Gitzelmann S, Vilne B, Bock F, Graf S, Schiemann M, Keller UB, Peschel C, Oostendorp RA.
Stromal pleiotrophin regulates repopulation behavior of hematopoietic stem cells.
Blood. 2011 Jul 25.

Meyer Zum Büschenfelde C, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H, Schwaiger M, Peschel C, Lordick F, Krause BJ.
18F-FDG PET-Guided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial.
J Nucl Med. 2011 Jul 15

Peschel C, Nitschmann S.
Chemoimmunotherapy as a new strategy in chronic lymphocytic leukemia : German CLL study.
Internist (Berl). 2011 Jul 14.

Krönig H, Falchner KJ, Odendahl M, Brackertz B, Conrad H, Muck D, Hein R, Blank C, Peschel C, Haller B, Schulz S, Bernhard H.
PD-1 expression on MelanA-reactive T cells increases during progression to metastatic disease.
Int J Cancer. 2011 Jun 29. doi: 10.1002/ijc.26272.

Albers C, Illert AL, Miething C, Leischner H, Thiede M, Peschel C, Duyster J.
An RNAi based system for loss of function analysis identifies Raf1 as a crucial mediator of BCR-ABL driven leukemogenesis.
Blood. 2011 Jun 29.

Ihbe-Heffinger A, Paessens BJ, von Schilling C, Shlaen M, Gottschalk N, Berger K, Bernard R, Kiechle M, Peschel C, Jacobs VR.
Management of febrile neutropenia - a german prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
Onkologie. 2011;34(5):241-6.

Paessens B, Ihbe-Heffinger A, von Schilling C, Shlaen R, Bernard R, Peschel C, Schramm W, Berger K.
Blood component use and associated costs after standard dose chemotherapy-a prospective analysis of routine hospital care in lymphoproliferative disorders and NSCLC in Germany.
Support Care Cancer. 2011 May 12.

Parmar A, Marz S, Rushton S, Holzwarth C, Lind K, Kayser S, Döhner K, Peschel C, Oostendorp RA, Goetze KS.
Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first generation FLT3 tyrosine kinase inhibitors.
Cancer Res. 2011 May 5.

Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ, Siewert JR, Büschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Peschel C, Schwaiger M, Lordick F, Krause BJ.
Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer.
Ann Surg Oncol. 2011 May 3.

Ströhlein MA, Lordick F, Rüttinger D, Grützner KU, Schemanski OC, Jäger M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM.
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.
Onkologie. 2011;34(3):101-8. Epub 2011 Feb 18.

von Bubnoff N, Gorantla SP, Engh RA, Oliveira TM, Thöne S, Aberg E, Peschel C, Duyster J.
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
Oncogene. 2011 Feb 24;30(8):933-43.

Paessens BJ, von Schilling C, Berger K, Shlaen M, Müller-Thomas C, Bernard R, Peschel C, Ihbe-Heffinger A.
Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients.
Ann Oncol. 2011 Feb 22.

Huber S, Oelsner M, Decker T, Zum Büschenfelde CM, Wagner M, Lutzny G, Kuhnt T, Schmidt B, Oostendorp RA, Peschel C, Ringshausen I.
Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.
Leukemia. 2011 Feb 4.

Kancha RK, Peschel C, Duyster J.
The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors.
J Thorac Oncol. 2011 Feb;6(2):387-92.


2010

Theisen J, Krause B, Peschel C, Schmid R, Geinitz H, Friess H.
Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer.
World J Gastrointest Surg. 2009 Nov 30;1(1):30-7.PMID: 21160793


von Bubnoff N, Gorantla SP, Engh RA, Oliveira TM, Thöne S, Aberg E, Peschel C, Duyster J.
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
Oncogene. 2010 Oct 25.

Gorantla SP, Dechow TN, Grundler R, Illert AL, Meyer Zum Büschenfelde C, Kremer M, Peschel C, Duyster J.
Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.
Blood. 2010 Aug 9.

Kaltz N, Ringe J, Holzwarth C, Charbord P, Niemeyer M, Jacobs VR, Peschel C, Häupl T, Oostendorp RA.
Novel markers of mesenchymal stem cells defined by genome-wide gene expression analysis of stromal cells from different sources.
Exp Cell Res. 2010 Oct 1;316(16):2609-17.

Keller U, Huber J, Nilsson JA, Fallahi M, Hall MA, Peschel C, Cleveland JL.
Myc suppression of Nfkb2 accelerates lymphomagenesis.
BMC Cancer. 2010 Jul 2;10:348.

Baumgart A, Seidl S, Vlachou P, Michel L, Mitova N, Schatz N, Specht K, Koch I, Schuster T, Grundler R, Kremer M, Fend F, Siveke JT, Peschel C, Duyster J, Dechow T.
ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer.
Cancer Res. 2010 Jul 1;70(13):5368-78.

Decker T, Bogner C, Oelsner M, Peschel C, Ringshausen I.
Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors.
Ann Hematol. 2010 Jun 11.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.
Improved survival with ipilimumab in patients with metastatic melanoma.
N Engl J Med. 2010 Aug 19;363(8):711-23.

von Bubnoff N, Rummelt C, Menzel H, Sigl M, Peschel C, Duyster J.
Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
Leukemia. 2010 Aug;24(8):1523-5.

den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA, Keller U.
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.
Blood. 2010 Jun 2

Ringshausen I, Feuerstacke Y, Krainz P, den Hollander J, Hermann K, Buck A, Peschel C, Meyer Zum Bueschenfelde C.
Antifungal therapy with itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts.
Cancer Res. 2010 Jun 1;70(11):4292-6.

Pechloff K, Holch J, Ferch U, Schweneker M, Brunner K, Kremer M, Sparwasser T, Quintanilla-Martinez L, Zimber-Strobl U, Streubel B, Gewies A, Peschel C, Ruland J.
The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma.
J Exp Med. 2010 May 10;207(5):1031-44.

Old JB, Kratzat S, Hoellein A, Graf S, Nilsson JA, Nilsson L, Nakayama KI, Peschel C, Cleveland JL, Keller UB.
Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.
Mol Cancer Res. 2010 Mar;8(3):353-62.

Keller U, von Bubnoff N, Peschel C, Duyster J.
Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy.
J Cell Mol Med. 2010 Apr;14(4):805-17. Epub 2010 Feb 16.

Deenick, E, Hall, H., Po, L, Saibil, S., Alisha R. Elford, Ruland, J., Gerondakis, S., Mak, T. and Ohashi. P.
c-rel acts via two distinct mechanisms to both positively and negatively regulate peripheral T cell tolerance.
Eur J Immunol. 2010 Mar;40(3):867-77.

Verbeek M, Fend F, Licht T, Büschenfelde CM, Stollfuss J, Peschel C, Duyster J.
T-cell lymphoproliferative disorder potentially induced by imatinib in a patient with GIST.
Nat Rev Clin Oncol. 2010 Feb;7(2):116-9.

Fischer P, Rümmler M, Schulz C, Peschel C, Ott I, Oostendorp RA.
Altered adhesive properties of cord blood endothelial outgrowth cells expressing IL-1ra.
Immunol Cell Biol. 2010 Mar;88(3):313-20.

Liang X, Weigand LU, Schuster IG, Eppinger E, van der Griendt JC, Schub A,
Leisegang M, Sommermeyer D, Anderl F, Han Y, Ellwart J, Moosmann A, Busch DH, Uckert W, Peschel C, Krackhardt AM:
A single TCR alpha-chain with dominant peptide recognition in the allorestricted HER2/neu-specific T cell repertoire.
J Immunol. 2010 Feb 1;184(3):1617-29.

Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Röthling N, Schuster T, Keller G, Fend F, Peschel C.
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Br J Cancer. 2010 Feb 2;102(3):500-5.

Götze, KS., Müller-Thomas, K.,Peschel, C.
The Role of azacitidine in the management of myelodysplastic syndromes (MDS)
Cancer Management and Research in press


2009

Han Y, Eppinger E, Schuster IG, Weigand LU, Liang X, Kremmer E, Peschel C,
Krackhardt AM:
Formin-like 1 (FMNL1) is regulated by N-terminal myristoylation and induces polarized membrane blebbing
J Biol Chem. 2009 Nov 27;284(48):33409-17.

Tusche, M., Ward, L., Vu, F., McCarthy, D., Quintela-Fandino, M., Ruland, J., Gommerman, J.L.  and Mak, T. W.
Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets.
J Exp Med. 2009 Nov 23;206(12):2671-83.

Poeck, H., Bscheider, M., Gross, O., Finger, K., Hannesschläger, K., Schlee, M., Rebsamen, M., Rothenfusser, S., Akira, S., Endres, S., Peschel, C., Hartmann, G., Hornung, V., and Ruland, J.
Rig-I is a dual activator of Card9 signaling and the inflammasome for IL-1β production upon RNA virus recognition.
Nat Immunol Published online, doi:10.1038/ni.1824

Renström J, Istvanffy R, Gauthier K, Shimono A, Mages J, Jardon-Alvarez
A, Kröger M, Schiemann M, Busch DH, Esposito I, Lang R, Peschel C,
Oostendorp RAJ.
Secreted frizzled-related protein 1 extrinsically regulates cycling activity and maintenance of hematopoietic stem cells.
Cell Stem Cell. 2009;5:157-67.

Bandi SR, Brandts C, Rensinghoff M, Grundler R, Tickenbrock L, Kohler 
G, Duyster J, Berdel WE, Muller-Tidow C, Serve H, Sargin B.
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and 
a myeloproliferative disease.

Blood. 2009 Sep 4.

Ferch, U., Kloo, B., Gewies, A., Pfänder, V., Düwel, M., Peschel, C., Krappmann, D., and Ruland, J.
Inhibition of MALT1 Protease Activity is Selectively Toxic for Activated B Cell like Diffuse Large B Cell Lymphoma Cells.
J Exp Med; 206, 2313-2320.

Glocker, E., Hennigs, A., Nabavi, M., Schäffer, A., Woellner, C., Salzer, U., Pfeifer, D., Veelken, H., Warnatz, K., Tahami, F., Jamal, S., Manguiat, A., Rezaei, N., Amirzargar, A., Plebani, A., Hannesschläger, N., Gross, O., Ruland, J. and Grimbacher. B.
Increased susceptibility to fungal infections/chronic mucocutaneous candidiasis can be due to a homozygous loss-of-function mutation in CARD9.
N Engl J Med 361, 1727-1735

Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S, 
Pogacic V, Villa A, Ehret S, Berridge G, Spoo A, Dierks C, Biondi A, 
Knapp S, Duyster J, Schwaller J.
Dissection of PIM serine/threonine kinases in FLT3-ITD-induced 
leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated 
homing and migration.

J Exp Med. 2009 Aug 31;206(9):1957-70.

Krönig H, Hofer K, Conrad H, Guilaume P, Müller J, Schiemann M, Lennerz V, Cosma A, Peschel C, Busch DH, Romero P, Bernhard H.
Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
Int J Cancer
. 2009 Aug 1;125(3):649-55.

Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Bugat R.
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Qual Life Res. 2009 Jul 1.

Robinson, M., Osorio, F., Rosas, M., Schweighoffer, E., Gross, O., Verbeek, S., Ruland, J., Tybulewicz, V., Brown, G.D., Taylor, P., and Reis e Sousa, C.
Dectin-2 is a Syk-coupled pattern recognition receptor that contributes to adaptive immunity to fungal infection.
J Exp Med 206: 2037-51

Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F.
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.
Ann Oncol. 2009 Jun 23.

Düwel, M., Welteke, V., Oeckinghaus, V., Baens, M., Kloo, B., Ferch, U., Darnay, B., Ruland, J., Marynen, P., and Krappmann, D.
A20 negatively regulates T cell receptor signaling to NF-κB by cleaving Malt1 ubiquitin chains.
J Immunol 182: 7718-28

Hauswald S, Duque-Afonso J, Wagner MM, Schertl FM, Lübbert M, Peschel C, Keller U, Licht T.
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Clin Cancer Res. 2009 Jun 1;15(11):3705-15. Epub 2009 May 19.

Gross, O., Poeck, H., Bscheider, M., Dostert, C., Hannesschläger, N., Endres, S., Hartmann, G., Tardivel, A., Schweighoffer, E., Tybulewicz, V., Mocsai, A., Tschopp, J., and Ruland, J.
Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence.
Nature 459: 433-6

Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, 
Brecht A, Duyster J, Haferlach T, Huber C, Fischer T.
Identification of a novel type of ITD mutations located in 
nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.

Blood. 2009 Apr 23;113(17):4074-7. Epub 2008 May 15.

Steinberg, C., Eisenächer, K., Gross, O., Reindl, W., Schmitz, F., Ruland, J.,Krug, A.
The IFN regulatory factor 7-dependent type I IFN response is not essential for early resistance against murine cytomegalovirus infection.
Eur J Immunol 39(4): 1007-18.

Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team.
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Lancet. 2009 May 2;373(9674):1525-31.

Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U.
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
J Clin Oncol. 2009 Jun 10;27(17):2823-30.

von Bubnoff N, Engh RA, Aberg E, Sänger J, Peschel C, Duyster J.
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
Cancer Res. 2009 Apr 1;69(7):3032-41. Epub 2009 Mar 24.

Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, 
Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander 
SK, Humphries KR, Hiddemann W, Spiekermann K.
CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core 
binding factor/11q deletion acute myeloid leukemia/myelodysplastic 
syndrome subtypes.

Clin Cancer Res. 2009 Apr 1;15(7):2238-47. Epub 2009 Mar 10.

Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA; IRIS Investigators.
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
Leukemia. 2009 Jun;23(6):1054-61.

Sebastian M, Kiewe P, Schuette W, Brust D, Peschel C, Schneller F, Rühle KH, Nilius G, Ewert R, Lodziewski S, Passlick B, Sienel W, Wiewrodt R, Jäger M, Lindhofer H, Friccius-Quecke H, Schmittel A.
Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.
J Immunother. 2009 Feb-Mar;32(2):195-202.

Werninghaus, K., Babiak, A., Gross, O., Hölscher, C., Dietrich, H., Agger, E., Mages, J., Mocsai, A., Schoenen, H., Finger, K., Nimmerjahn, F., Brown, G., Kirschning, C., Heit, A., Andersen, P., Wagner, H., Ruland, J*. Lang, R.*
Adjuvanticity of a synthetic cord factor analog for subunit M. tuberculosis vaccination requires FcRγ-Syk-Card9-dependent innate immune activation.
J Exp Med 206, 89-97. (*equal senior authorship).

Abbrederis K, Lorenzen S, Rothling N, Ihbe-Heffinger A, Schuster T, Peschel C, Lordick F.
Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
Onkologie. 2009 Feb;32(1-2):30-4.

Rosenberg R, Herrmann K, Gertler R, Kunzli B, Essler M, Lordick F, Becker K, Schuster T, Geinitz H, Maak M, Schwaiger M, Siewert JR, Krause B.
The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT.
Int J Colorectal Dis 2009; 24: 191-200.

Schlenk RF, Dohner K, Kneba M, Gotze K, Hartmann F, Del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Spath D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Frohling S, Dohner H.
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.
Haematologica 2009; 94: 54-60.

Heidel F, Lipka DB, Mirea FK, Mahboobi S, Grundler R, Kancha RK, 
Duyster J, Naumann M, Huber C, Böhmer FD, Fischer T.
Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD 
tyrosine kinase and partially overcome resistance to PKC412A in vitro.

Br J Haematol. 2009 Mar;144(6):865-74. Epub 2009 Jan 16.

Kancha RK, von Bubnoff N, Peschel C, Duyster J.
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Clin Cancer Res. 2009 Jan 15;15(2):460-7.

2008

Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, Kiechle M, Lordick F, Meindl A.
Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
PLoS ONE 2008; 3: e4003.

Schauer M, Stein H, Lordick F, Feith M, Theisen J, Siewert JR.
Results of a multimodal therapy in patients with stage IV Barrett's adenocarcinoma.
World J Surg 2008; 32: 2655-2660.

Langer R, Ott K, Specht K, Becker K, Lordick F, Burian M, Herrmann K, Schrattenholz A, Cahill MA, Schwaiger M, Hofler H, Wester HJ.
Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response.
Clin Cancer Res 2008; 14: 8279-8287.

Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ.
Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study.
Clin Cancer Res 2008; 14: 2012-2018.

Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, Schmidt A, Anz D, Bscheider M, Schwerd T, Berking C, Bourquin C, Kalinke U, Kremmer E, Kato H, Akira S, Meyers R, Hacker G, Neuenhahn M, Busch D, Ruland J, Rothenfusser S, Prinz M, Hornung V, Endres S, Tuting T, Hartmann G.
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma.
Nat Med 2008; 14: 1256-1263.

Ruland J.
CARD9 signaling in the innate immune response.
Ann N Y Acad Sci 2008; 1143: 35-44.

Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, Roethling N, Höfler H, Ott K, Peschel C, Siewert JR, Molls M, Lordick F.
Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial.
Br J Cancer. 2008 Sep 16.

Kancha RK, von Bubnoff N, Miething C, Peschel C, Götze KS, Duyster J.
Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.
Haematologica. 2008 Aug 25.

Graf N, Herrmann K, den Hollander J, Fend F, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, Büschenfelde CM, Peschel C, Schwaiger M, Dechow T, Buck AK.
Imaging Proliferation to Monitor Early Response of Lymphoma to Cytotoxic Treatment.
Mol Imaging Biol. 2008 Aug 14.

Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C.
A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.
Ann Hematol. 2008 Aug 14.

Müller-Thomas C, Schuster T, Peschel C, Götze KS.
A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Ann Hematol. 2008 Aug 12.

Kuhn KA, Knoll A, Mewes HW, Schwaiger M, Bode A, Broy M, Daniel H, Feussner H, Gradinger R, Hauner H, Höfler H, Holzmann B, Horsch A, Kemper A, Krcmar H, Kochs EF, Lange R, Leidl R, Mansmann U, Mayr EW, Meitinger T, Molls M, Navab N, Nüsslin F, Peschel C, Reiser M, Ring J, Rummeny EJ, Schlichter J, Schmid R, Wichmann HE, Ziegler S.
Informatics and medicine. From molecules to populations.
Methods Inf Med. 2008;47(4):283-95.

Kaltz N, Funari A, Hippauf S, Delorme B, Noël D, Rimminucci M, Jacobs VR, Häupl T, Jorgensen C, Charbord P, Peschel C, Bianco P, Oostendorp RA.
In-vivo Osteoprogenitor Potency of Human Stromal Cells from Different Tissues does not Correlate with Expression of POU5F1 or its Pseudogenes.
Stem Cells. 2008 Jul 10.

Meier R, Piert M, Piontek G, Rudelius M, Oostendorp RA, Senekowitsch-Schmidtke R, Henning TD, Wels WS, Uherek C, Rummeny EJ, Daldrup-Link HE.
Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors.
Nucl Med Biol 2008; 35: 579-588.

Menzel H, Muller A, Von Schilling C, Licht T, Peschel C, Keller U
Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: Analysis of remission induction and stem cell mobilization.
Leuk Lymphoma. 2008 Jul;49(7):1337-1344.

Fanta S, Sonnenberg M, Skorta I, Duyster J, Miething C, Aulitzky WE, van der Kuip H.
Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.
Oncogene 2008; 27: 4380-4384.

Ledran MH, Krassowska A, Armstrong L, Dimmick I, Renstrom J, Lang R, Yung S, Santibanez-Coref M, Dzierzak E, Stojkovic M, Oostendorp RA, Forrester L, Lako M.
Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches.
Cell Stem Cell 2008; 3: 85-98.

Meyer zum Büschenfelde C, Feuerstacke Y, Götze KS, Scholze K, Peschel C.
GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment.
Cancer Res. 2008 Jul 1;68(13):5414-22.

Homig-Holzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Muller W, Quintanilla-Martinez L, Gewies A, Ruland J, Rajewsky K, Zimber-Strobl U.
Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis.
J Exp Med 2008; 205: 1317-1329.

Bader FG, Lordick F, Fink U, Becker K, Hofler H, Busch R, Siewert JR, Ott K.
Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up.
Onkologie 2008; 31: 366-372.

Kremer M, Horn T, Koch I, Dechow T, Gattenloehner S, Pfeiffer W, Quintanilla-Martinez L, Fend F.
Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells.
Am J Surg Pathol 2008; 32: 928-935.

Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R.
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Ann Oncol. 2008 Jun 16.

Conrad H, Gebhard K, Krönig H, Neudorfer J, Busch DH, Peschel C, Bernhard H.
CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4.
J Immunol. 2008 Jun 15;180(12):8135-45.

McCullar V, Oostendorp R, Panoskaltsis-Mortari A, Yun G, Lutz CT, Wagner JE, Miller JS.
Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15.
Exp Hematol 2008; 36: 598-608.

Oostendorp RA, Gilfillan S, Parmar A, Schiemann M, Marz S, Niemeyer M, Schill S, Hammerschmid E, Jacobs VR, Peschel C, Götze KS.
Oncostatin M-mediated Regulation Of KIT-Ligand-Induced ERK Signaling Maintains Hematopoietic Repopulating Activity Of Lin- CD34+ CD133+ Cord Blood Cells.
Stem Cells. 2008 May 22

Schaefer M, Reiling N, Fessler C, Stephani J, Taniuchi I, Hatam F, Yildirim AO, Fehrenbach H, Walter K, Ruland J, Wagner H, Ehlers S, Sparwasser T.
Decreased pathology and prolonged survival of human DC-SIGN transgenic mice during mycobacterial infection.
J Immunol 2008; 180: 6836-6845.

Buck AK, Herrmann K, Büschenfelde CM, Juweid ME, Bischoff M, Glatting G, Weirich G, Möller P, Wester HJ, Scheidhauer K, Dechow T, Peschel C, Schwaiger M, Reske SN.
Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine.
Clin Cancer Res 2008; 14: 2970-2977.

Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brecht A, Duyster J, Haferlach T, Huber C, Fischer T.
Identification of a novel type of ITD mutations located in non-juxtamembrane domains of the FLT3 tyrosine kinase receptor.
Blood. 2009 Apr 23;113(17):4074-7.

Beer AJ, Holzapfel K, Neudorfer J, Piontek G, Settles M, Krönig H, Peschel C, Schlegel J, Rummeny EJ, Bernhard H.
Visualization of antigen-specific human cytotoxic T lymphocytes labeled with superparamagnetic iron-oxide particles .
Eur Radiol 2008; 18: 1087-1095.

Bremm A, Walch A, Fuchs M, Mages J, Duyster J, Keller G, Hermannstadter C, Becker KF, Rauser S, Langer R, von Weyhern CH, Hofler H, Luber B.
Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.
Cancer Res 2008; 68: 707-714.

Abbrederis K, Lorenzen S, von Weikersthal LF, Vehling-Kaiser U, Schuster T, Rothling N, Peschel C, Lordick F.
Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer Results of a phase II study in elderly patients or patients with impaired performance status.
Crit Rev Oncol Hematol 2008; 66: 84-90.

Gross O, Grupp C, Steinberg C, Zimmermann S, Strasser D, Hannesschlager N, Reindl W, Jonsson H, Huo H, Littman DR, Peschel C, Yokoyama WM, Krug A, Ruland J.
Multiple ITAM-coupled NK cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-{kappa}B and MAPK activation to selectively control cytokine production.
Blood. 2008 Jan 11;

2007

Lorenzen S, Herrmann K, Weber WA, Wieder H, Hennig M, Ott K, Bredenkamp R, Peschel C, Schwaiger M, Lordick F.
Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET.
Nuklearmedizin. 2007;46(6):263-70

Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, Peschel C, Lordick F, Schwaiger M.
Comparison of Integrin {alpha}v{beta}3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG.
J Nucl Med. 2007 Dec 12;

Peschel C, Hartmann JT, Schmittel A, Bokemeyer C, Schneller F, Keilholz U, Ruchheidt D, Millan S, Izquierdo MA, Hofheinz RD.
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
Lung Cancer. 2007 Dec 1

Siewert JR, Lordick F, Ott K, Stein HJ, Weber WA, Becker K, Peschel C, Fink U, Schwaiger M.
Induction Chemotherapy in Barrett Cancer: Influence on Surgical Risk and Outcome.
Ann Surg. 2007 Oct;246(4):624-631.

Kancha RK, Grundler R, Peschel C, Duyster J.
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Exp Hematol. 2007 Oct;35(10):1522-6.

Schuster IG, Busch DH, Eppinger E, Kremmer E, Milosevic S, Hennard C, Kuttler C, Ellwart JW, Frankenberger B, Nößner E, Salat C, Bogner C, Borkhardt A, Kolb HJ, and Krackhardt AM: Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematological and other malignancies; Blood 2007; 110 :2931-2939,

Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, Göktuna 
SI, Neuenhahn M, Fierer J, Paxian S, Van Rooijen N, Xu Y, O'Cain T, 
Jaffee BB, Busch DH, Duyster J, Schmid RM, Eckmann L, Karin M.
NF-kappaB is a negative regulator of IL-1beta secretion as revealed by 
genetic and pharmacological inhibition of IKKbeta.
Cell. 2007 Sep 7;130(5):918-31.

Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T.
The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells.
Leukemia. 2007 Sep 6;

Gotze KS, Hoffmann D, Schatzl HM, Peschel C, Fend F, Decker T.
Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.
Haematologica. 2007 Sep;92(9):1282-3.

Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Hofler H, Fink U, Peschel C, Schwaiger M, Siewert JR.
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Lancet Oncol. 2007 Sep;8(9):797-805.

Ferch U, Buschenfelde CM, Gewies A, Wegener E, Rauser S, Peschel C, Krappmann D, Ruland J.
MALT1 directs B cell receptor-induced canonical nuclear factor-kappaB signaling selectively to the c-Rel subunit.
Nat Immunol. 2007 Sep;8(9):984-91. Epub 2007 Jul 29.

Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C, Lordick F.
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
Ann Oncol. 2007 Jul 28;

Gotze KS, Schiemann M, Marz S, Jacobs VR, Debus G, Peschel C, Oostendorp RA.
CD133-enriched CD34(-) (CD33/CD38/CD71)(-) cord blood cells acquire CD34 prior to cell division and hematopoietic activity is exclusively associated with CD34 expression.
Exp Hematol. 2007 Sep;35(9):1408-14. Epub 2007 Jul 25.;

Bernhard H, Neudorfer J, Gebhard K, Conrad H, Hermann C, Nahrig J, Fend F, Weber W, Busch DH, Peschel C.
Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.
Cancer Immunol Immunother. 2007 Jul 24;

Scheich F, Duyster J, Peschel C, Bernhard H.
The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens.
Blood. 2007 Jun 19;

Herrmann K, Wieder HA, Buck AK, Schoffel M, Krause BJ, Fend F, Schuster T, Meyer Zum Buschenfelde C, Wester HJ, Duyster J, Peschel C, Schwaiger M, Dechow T.
Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma.
Clin Cancer Res. 2007 Jun 15;13(12):3552-8.

Menzel H, von Bubnoff N, Hochhaus A, Haferlach C, Peschel C, Duyster J.
Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib.
Bone Marrow Transplant. 2007 Jul;40(1):83-4. Epub 2007 Apr 23

Sargin B, Choudhary C, Crosetto N, Schmidt MH, Grundler R, Rensinghoff 
M, Thiessen C, Tickenbrock L, Schwäble J, Brandts C, August B, 
Koschmieder S, Bandi SR, Duyster J, Berdel WE, Müller-Tidow C, Dikic 
I, Serve H.
Flt3-dependent transformation by inactivating c-Cbl mutations in AML.
Blood. 2007 Aug 1;110(3):1004-12. Epub 2007 Apr 19.

Bassermann F, von Klitzing C, Illert AL, Muench S, Morris SW, Pagano M, Peschel C, Duyster J.
Multisite phosphorylation of nipa at G2/M involves cyclin B1/CDK1.
J Biol Chem. 2007 Jun 1;282(22):15965-72. Epub 2007 Mar 27;

Miething C, Grundler R, Mugler C, Brero S, Hoepfl J, Geigl J, Speicher MR, Ottmann O, Peschel C, Duyster J.
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4594-9. Epub 2007 Mar 5.

The anticancer drug imatinib induces cellular autophagy.
Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J, Elsässer 
HP, Schätzl HM.
The anticancer drug imatinib induces cellular autophagy.
Leukemia. 2007 May;21(5):936-42. Epub 2007 Mar 1.

Neudorfer J, Schmidt B, Huster KM, Anderl F, Schiemann M, Holzapfel G, Schmidt T, Germeroth L, Wagner H, Peschel C, Busch DH, Bernhard H.
Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens.
J Immunol Methods. 2007 Mar 30;320(1-2):119-31. Epub 2007 Jan 31.

Jost PJ, Weiss S, Ferch U, Gross O, Mak TW, Peschel C, Ruland J.
Bcl10/Malt1 Signaling Is Essential for TCR-Induced NF-{kappa}B Activation in Thymocytes but Dispensable for Positive or Negative Selection.
J Immunol. 2007 Jan 15;178(2):953-60.

2006

Krötz F, Keller M, Derflinger S, Schmid H, Gloe T, Bassermann F, 
Duyster J, Cohen CD, Schuhmann C, Klauss V, Pohl U, Stempfle HU, Sohn 
HY.
Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and 
superoxide formation by a Rac1-dependent mechanism.
Hypertension. 2007 Jan;49(1):201-8. Epub 2006 Nov 13.

Witzig R, Schonberger B, Fink U, Busch R, Gundel H, Sendler A, Peschel C, Siewert JR, Lordick F.
Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma.
Endoscopy. 2006 Nov;38(11):1122-6.

Klemm S, Zimmermann S, Peschel C, Mak TW, Ruland J.
Bcl10 and Malt1 control lysophosphatidic acid-induced NF-{kappa}B activation and cytokine production.
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):134-8. Epub 2006 Nov 9

Ringshausen I, Peschel C, Decker T.
Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machinery.
Curr Drug Targets. 2006 Oct;7(10):1349-59.

Jost P, Peschel C, Ruland J.
The Bcl10/Malt1 signaling pathway as a drug target in lymphoma.
Curr Drug Targets. 2006 Oct;7(10):1335-40.

Miething C, Peschel C, Duyster J.
Targeting the oncogenic tyrosine kinase NPM-ALK in lymphoma: the role of murine models in defining pathogenesis and treatment options.
Curr Drug Targets. 2006 Oct;7(10):1329-34.

Schmidt B, Kremer M, Gotze K, John K, Peschel C, Hofler H, Fend F.
Bone marrow involvement in follicular lymphoma: Comparison of histology and flow cytometry as staging procedures.
Leuk Lymphoma. 2006 Sep;47(9):1857-62.

Gross O, Gewies A, Finger K, Schafer M, Sparwasser T, Peschel C, Forster I, Ruland J.
Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity.
Nature.2006 Aug 10;442(7103):651-6. Epub 2006 Jul 12

Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C, Decker T.
Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Br J Haematol.2006 Jul 20;

Abbrederis K, Bassermann F, Schuhmacher C, Voelter V, Busch R, Roethling N, Sendler A, Siewert JR, Peschel C, Lordick F.
Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
Ann Thorac Surg. 2006 Jul;82(1):293-7.

von Bubnoff N, Gorantla SP, Thone S, Peschel C, Duyster J, Stover EH, Cools J, Gilliland DG.
The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).
Blood. 2006 Jun 15;107(12):4970-4972.

Schwaiger M, Peschel C.
Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy.
Eur J Nucl Med Mol Imaging. 2006 Jul;33 Suppl 13:1-5.

von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J.
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
Blood. 2006 Aug 15;108(4):1328-33. Epub 2006 Apr 13

Kastenmuller W, Drexler I, Ludwig H, Erfle V, Peschel C, Bernhard H, Sutter G.
Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity.
Virology. 2006 Jul 5;350(2):276-88. Epub 2006 Apr 3

Bogner C, Sandherr M, Perker M, Weick K, Ringshausen I, Peschel C, Decker T.
Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells.
Ann Hematol. 2006 Jul;85(7):458-62. Epub 2006 Mar 15.

Miething C, Feihl S, Mugler C, Grundler R, von Bubnoff N, Lordick F, Peschel C, Duyster J.
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.
Leukemia. 2006 Apr;20(4):650-7.

Bogner C, Peschel C, Decker T.
Targeting the proteasome in mantle cell lymphoma: A promising therapeutic approach.
Leuk Lymphoma. 2006 Feb;47(2):195-205.

Ringshausen I, Oelsner M, Weick K, Bogner C, Peschel C, Decker T.
Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL.
Leukemia. 2006 Mar;20(3):514-20.

Klemm S, Gutermuth J, Hultner L, Sparwasser T, Behrendt H, Peschel C, Mak TW, Jakob T, Ruland J.
The Bcl10-Malt1 complex segregates Fc{varepsilon}RI-mediated nuclear factor {kappa}B activation and cytokine production from mast cell degranulation.
J Exp Med. 2006 Feb 20;203(2):337-47. Epub 2006 Jan 23

2005

Lordick F, Peschel C, Siewert JR.
Antibody-based targeted therapy for gastric cancer.
Gastric Cancer 2005;8(4):206-8. No abstract available.

Jost PJ, Stengel SM, Huber W, Sarbia M, Peschel C, Duyster J.
Very severe iron-deficiency anemia in a patient with celiac disease and bulimia nervosa: a case report
Int J Hematol. 2005 Nov;82(4):310-1.

Bassermann F, Peschel C, Duyster J.Mitotic entry: a matter of oscillating destruction.Cell Cycle. 2005 Nov;4(11):1513-5. Epub 2005 Nov 21.

Hipp S, Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells Haematologica. 2005 Oct;90(10):1433-4.

von Bubnoff N, Gorantla SH, Kancha RK, Lordick F, Peschel C, Duyster J. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia. 2005 Jul 14; [Epub ahead of print]

Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hentrich M, Zumschlinge R, Dietzfelbinger H, Thoedtmann J, Hennig M, Seroneit T, Bredenkamp R, Duyster J, Peschel C. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer. 2005 Jul 25;93(2):190-4.

Bassermann F, von Klitzing C, Munch S, Bai RY, Kawaguchi H, Morris SW, Peschel C, Duyster J. NIPA Defines an SCF-Type Mammalian E3 Ligase that Regulates Mitotic Entry. Cell. 2005 Jul 15;122(1):45-57. Dengler J, von Bubnoff N, Decker T, Peschel C, Duyster J. Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. Leukemia. 2005 Jun 30; Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer. 2005 Jun 20;92(12):2129-33

Oostendorp RAJ, Robin C, Steinhoff C, Marz S, Bräuer R, Nuber UA, Dzierzak EA, Peschel C. Long-term maintenence of hematopoietic stem cells does not require contact with embryo-derived stromal cells in cocultures. Stem Cells,  2005 Jun;23(6):842-51

Lordick F, Ihbe-Heffinger A, Peschel C. Antiemetic prophylaxis in the chemotherapy of gastrointestinal tumours Z Gastroenterol. 2005 Apr;43(4):391-8.

Nieder C, Schneller F, Grosu AL, Peschel C, Molls M. Radiotherapy and Chemotherapy for Myoepithelioma of the Sellar Region Strahlenther Onkol. 2005 Apr;181(4):260-263

von Bubnoff N, Barwisch S, Speicher MR, Peschel C, Duyster J. A Cell-Based Screening Strategy that Predicts Mutations in Oncogenic Tyrosine Kinases: Implications for Clinical Resistance in Targeted Cancer Treatment. Cell Cycle. 2005 Mar 25;4(3) [Epub ahead of print]

Urschel S, Bassermann F, Bai RY, Muench S, Peschel C, Duyster J. Phosphorylation of Grb10 regulates its interaction with 14-3-3. J Biol Chem. 2005 Feb 18; [Epub ahead of print] Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce two distinct phenotypes in a murine bone marrow transplant model. Blood. 2005 Feb 17; [Epub ahead of print]

von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia. 2005 Feb;19(2):286-7.

Ringshausen I, Peschel C, Decker T. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: A new therapeutic option Leuk Lymphoma. 2005 Jan;46(1):11-9

Ott I, Keller U, Knoedler M, Götze KS, Doss K, Fischer P, Urlbauer K, Debus G, von Bubnoff N, Rudelius M, Schömig A, Peschel C, Oostendorp RAJ. Transplantation of endothelial-like cells expanded from CD34+ cells improve left ventricular function after experimental myocardial infarction. FASEB J. 2005 Apr 6;

Daldrup-Link HE, Rudelius M, Piontek G, Metz S, Brauer R, Debus G, Corot C, Schlegel J, Link TM, Peschel C, Rummeny EJ, Oostendorp RA Migration of Iron Oxide-labeled Human Hematopoietic Progenitor Cells in a Mouse Model: In Vivo Monitoring with 1.5-T MR Imaging Equipment Radiology. 2005 Jan;234(1):197-205

Oostendorp RAJ, Harvey K, Dzierzak EA. Generation of murine stromal cell lines: models for the microenvironment of the embryonic mouse aorta-gonads-mesonephros region. Methods Mol Biol. 2005; 290: 163-72. Bernhard H, Schmidt B, Busch DH, Peschel C Isolation and expansion of tumor-reactive cytotoxic T-cell clones for adoptive immunotherapy Methods Mol Med. 2005;109:175-84

2004

Ringshausen I, Dechow T, Schneller F, Weick K, Oelsner M, Peschel C, Decker T
Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells.
Leukemia. 2004 Dec;18(12):1964-70

Lordick F, Rosenberg R, Stein HJ, Peschel C, Siewert JR
Adjuvant therapy for colon cancer
Dtsch Med Wochenschr. 2004 Oct 29;129(44):2366-71

Von Bubnoff N, Peschel C, Duyster J.
An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes
Dtsch Med Wochenschr. 2004 Oct 1;129(40):2100-3

Von Bubnoff N, Veach DR, Van Der Kuip H, Aulitzky WE, Sanger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J.
A cell-based screen for resistance of Bcr-Abl positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
Blood. 2004 Sep 30

Voelter V, Schuhmacher C, Busch R, Peschel C, Siewert JR, Lordick F
Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer.
Ann Thorac Surg. 2004 Sep;78(3):1037-41

Decker T, Oelsner M, Kreitman RJ, Salvatore G, Wang QC, Pastan I, Peschel C, Licht T
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins
Blood. 2004 Apr 1;103(7):2718-26.

Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thodtmann J, Lordick F.
The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers.
Ann Oncol. 2004 Mar;15(3):526-36.

Lordick F, Stein HJ, Peschel C, Siewert JR.
Neoadjuvant therapy for oesophagogastric cancer
Br J Surg. 2004 May;91(5):540-51

Decker T, Hipp S, Hahntow I, Schneller F, Peschel C.
Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target.
Br J Haematol. 2004 Apr;125(2):141-8.

Volter V, Peschel C.
Is Lanreotide and/or Interferon Alfa an Adequate Therapy for Neuroendocrine Tumors?
J Clin Oncol. 2004 Feb 1;22(3):573.

Hahntow IN, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F, Peschel C, Decker T.
Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells
Leukemia. 2004 Feb 19
Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick CJ, Theobald M, Gschaidmeier H, Huber C, Fischer T.
The efficacy and safety of imatinib in adult patients with c-kit positive acute myeloid leukemia.
Blood. 2004 Jan 15

Fleischer K, Schmidt B, Kastenmuller W, Busch DH, Drexler I, Sutter G, Heike M, Peschel C, Bernhard H.
Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded
 with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat
 shock proteins in vitro.
J Immunol. 2004 Jan 1;172(1):162-9.

2003

Ruland J, Duncan GS, Wakeham A, Mak TW.
Differential requirement for Malt1 in T and B cell antigen receptor signaling.
Immunity. 2003 Nov;19(5):749-58

von Bubnoff N, Veach DR, Miller WT, Li W, Sanger J, Peschel C, Bornmann WG, Clarkson B, Duyster J.
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
Cancer Res. 2003 Oct 1;63(19):6395-404.
 
Nieder C, Jost PJ, Grosu AL, Peschel C, Molls M.
Report of a male patient with brain metastases from breast cancer.
Breast. 2003 Oct;12(5):345-7.

Miething C, Mugler C, Grundler R, Hoepfl J, Bai RY, Peschel C, Duyster J.
Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.
Leukemia. 2003 Sep;17(9):1695-9
Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C.
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Br J Cancer. 2003 Aug 18;89(4):630-3.

Miething C, Grundler R, Fend F, Hoepfl J, Mugler C, Von Schilling C, Morris SW, Peschel C, Duyster J.
The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct
 malignant phenotypes in a murine retroviral transplantation model.
Oncogene. 2003 Jul 24;22(30):4642-7.

Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J.
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
Blood. 2003 Jul 15;102(2):646-51.

Bogner C, Ringshausen I, Schneller F, Fend F, Quintanilla-Martinez L, Hacker G, Goetze K, Oostendorp R, Peschel C, Decker T.
Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells.
Br J Haematol. 2003 Jul;122(2):260-8

von Bubnoff N, Peschel C, Duyster J.
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec)
:a targeted oncoprotein strikes back.

Leukemia. 2003 May;17(5):829-38. Review.

Ouyang T, Bai RY, Bassermann F, Von Klitzing C, Klumpen S, Miething C, Morris SW, Peschel C, Duyster J.
Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).
J Biol Chem. 2003 Aug 8;278(32):30028-36.

Gundel H, Lordick F, Brandl T, Wurschmidt F, Schussler J, Leps B, Sendler A, Mert E, Pouget-Schors D, Von Schilling C, Peschel C, Sellschopp A.
Interdisciplinary psychoeducational intervention by oncologists proved helpful for cancer patients
Z Psychosom Med Psychother. 2003;49(3):246-61.

Lordick F, Hentrich M, Decker T, Hennig M, Pohlmann H, Hartenstein R, Peschel C.
Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study.
Br J Haematol. 2003 Mar;120(6):1073-8.

von Schilling C.
Immunotherapy with anti-CD20 compounds.
Semin Cancer Biol. 2003 Jun;13(3):211-22

Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, Peschel C.
Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin.
Blood. 2003 Jan 1;101(1):278-85.

Bogner C, Schneller F, Hipp S, Ringshausen I, Peschel C, Decker T.
Cycling B-CLL cells are highly susceptible to inhibition of the proteasome. Involvement of p27, early D-type cyclins, Bax,and caspase-dependent and - independent pathways.
Exp Hematol. 2003 Mar;31(3):218-25.

Drexler I, Staib C, Kastenmuller W, Stevanovic S, Schmidt B, Lemonnier FA, Rammensee HG, Busch DH, Bernhard H, Erfle V, Sutter G. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):217-22. 

2002

Wolfl M, Batten WY, Posovszky C, Bernhard H, Berthold F.
Gangliosides inhibit the development from monocytes to dendritic cells
Clin Exp Immunol. 2002 Dec;130(3):441-8.
Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C, Decker T.
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.
Blood. 2002 Nov 15;100(10):3741-8.
Keller U, Götze KS, Duyster J, Schmidt B, Rose-John S, Peschel C.
Murine stromal cells producing hyper-interleukin-6 and Flt3 ligand support expansion of early human hematopoietic progenitor cells without need of exogenous growth factors.
Leukemia. 2002 Oct;16(10):2122-8.

von Schilling C.
Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? Against.
Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1254-6. 

Krackhardt AM, Witzens M, Harig S, Hodi S, Zauls J, Barrett P, Gribben JG: Identification of tumor associated antigens in chronic lymphocytic leukemia by SEREX; Blood 2002; 100: 2123-2131.

Hoepfl J, Miething C, Grundler R, Gotze KS, Peschel C, Duyster J.
Effects of imatinib on bone marrow engraftment in syngeneic mice.
Leukemia. 2002 Sep;16(9):1584-8.

Lordick F, Gundel H, von Schilling C, Wurschmidt F, Leps B, Sendler A, Schussler J, Brandl T, Peschel C, Sellschopp A.
Structured patient education in oncology. A prospective study for implementing and effectiveness of interdisciplinary psycho-educational group intervention at a German university clinic
Med Klin (Munich). 2002 Aug 15;97(8):449-54.

Bernhard, H., Knutson, K.L. Salazarm L., Schiffman, K., and Disis, M.L. 
Vaccination against the HER-2/neu oncogenic protein. 
Endocrine-Related Cancer 9: 33-44, 2002.

Jahn T, Seipel P, Coutinho S, Urschel S, Schwarz K, Miething C, Serve H, Peschel C, Duyster J.
Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain.
Oncogene. 2002 Jul 4;21(29):4508-20.

Knabel, M., Franz, T.J., Schiemann, M., Wulf, A., Villmow, B., Schmidt, B., Bernhard, H., Wagner, H., and Busch, D. 
Reversible MHC multimer staining for functional isolation of T cell populations and effective adoptive transfer. 
Nature Med 8: 631-638, 2002.

Fuchs M, Hutzler P, Brunner I, Schlegel J, Mages J, Reuning U, Hapke S, Duyster J, Hirohashi S, Genda T, Sakamoto M, Uberall F, Hofler H, Becker KF, Luber B.
Motility enhancement by tumor-derived mutant E-cadherin is sensitive to treatment with epidermal growth factor receptor and phosphatidylinositol 3-kinase inhibitors.
Exp Cell Res. 2002 Jun 10;276(2):129-41.

Licht T, Peschel C.
Restoration of transgene expression in hematopoietic cells with drug-selectable marker genes.
Curr Gene Ther. 2002 May;2(2):227-34.

Meyer zum Büschenfelde, C., Hermann, C., Schmidt, B., Peschel, C. and Bernhard, H. 
Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances lysis of HER2-overexpressing tumor cells by class-I-restricted HER2-specific cytotoxic T lymphocytes.
Cancer Res 62: 2244-2247, 2002.

Bai, R. Y., Koester, C., Ouyang, T., Hahn, S. A., Hammerschmidt, M., Peschel, C., and
Duyster, J. (2002).
SMIF, a Smad4-interacting protein that functions as a co-activator in  TGFbeta signalling.
Nat Cell Biol. 2002 Mar;4(3):181-90.

Krackhardt AM, Harig S, Witzens M, Broderick R, Barrett P, Gribben JG: T cell responses against chronic lymphocytic leukemia cells; implications for immunotherapy; Blood 2002; 100: 167-173.

Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, Peschel C.
Blood, accepted Rapamycin induced G1 Arrest in cycling B-CLL cells is assocoated with reduced expression of cyclin D3, cyclin E, cyclin A and surviving.
Leukemia. 2002 Mar;16(3):327-34.

von Bubnoff, N., Schneller, F., Peschel, C., and Duyster, J.
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.
Lancet 359, 487-91.

Decker T, Hipp S, Kreitman RJ, Pastan I, Peschel C, Licht T.
Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.
Blood. 2002 Feb 15;99(4):1320-6.

Jahn, T., Seipel, P., Urschel, S., Peschel, C., and Duyster, J.
Role for the adaptor protein Grb10 in the activation of Akt.
Mol Cell Biol 22, 979-91.




2010 · III. Medizinische Klinik (Hämatologie / Onkologie) am Klinikum rechts der Isar der Technischen Universität München